Atossa Therapeutics Executes Contingent Value Rights Agreement for Shareholders

Key Facts

1Atossa Therapeutics entered into a definitive Contingent Value Rights (CVR) agreement providing shareholders participation in priority review voucher proceeds.

2Shareholders of record as of October 19, 2026, will receive one stapled CVR for each share of common stock held.

3The CVRs entitle holders to 25% of net proceeds from the monetization of the first qualifying priority review voucher, capped at $50 million.

Atossa Therapeutics entered into a definitive Contingent Value Rights (CVR) agreement providing shareholders participation in priority review voucher proceeds. PR Newswire reported that shareholders of record as of October 19, 2026, will receive one stapled CVR for each share of common stock held, entitling holders to 25% of net proceeds from the monetization of the first qualifying priority review voucher, capped at an aggregate of $50 million.

This corporate action follows a session where ATOS closed at $2.42 on October 8, 2026, with the stock trading between a day low of $2.38 and a high of $2.48. The agreement with VStock Transfer formalizes a previously announced plan to allow shareholders to benefit from potential financial upside linked to the company's regulatory milestones and voucher monetization.